2019
Meta-analysis of placebo group dropout in adult antidepressant trials
Li F, Nasir M, Olten B, Bloch MH. Meta-analysis of placebo group dropout in adult antidepressant trials. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2019, 98: 109777. PMID: 31697973, DOI: 10.1016/j.pnpbp.2019.109777.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPlacebo leadAntidepressant trialsDiagnostic indicationsPlacebo-controlled trialStratified subgroup analysisBaseline illness severityMore study visitsDropout rateOverall dropout rateFreeman-Tukey transformationLonger trial durationEarlier publication yearPlacebo groupIllness severitySubgroup analysisDepressive disorderStudy visitMeta-AnalysisTrial durationAnxiety disordersTrialsEfficiency of trialsSubject burdenDisordersMeta-Analysis of Placebo Response in Adult Antidepressant Trials
Li F, Nasir M, Olten B, Bloch MH. Meta-Analysis of Placebo Response in Adult Antidepressant Trials. CNS Drugs 2019, 33: 971-980. PMID: 31573058, DOI: 10.1007/s40263-019-00662-y.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive Agents, Second-GenerationAnxietyClinical Trials as TopicDepressionHumansObsessive-Compulsive DisorderRandomized Controlled Trials as TopicConceptsPlacebo response ratesPlacebo improvementSymptom improvementObsessive-compulsive disorderResponse rateDiagnostic indicationsAntidepressant trialsRandomized placebo-controlled trialPlacebo-controlled trialStratified subgroup analysisSecond-generation antidepressantsPlacebo comparison groupFuture antidepressantsSubgroup analysisClinical trialsPlacebo responseTrial characteristicsGreater magnitudeDepression trialsMeta-AnalysisUS sitesTrial durationAntidepressantsLanguage limitsMean difference
2012
Systematic review: Pharmacological treatment of tic disorders – Efficacy of antipsychotic and alpha-2 adrenergic agonist agents
Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review: Pharmacological treatment of tic disorders – Efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neuroscience & Biobehavioral Reviews 2012, 37: 1162-1171. PMID: 23099282, PMCID: PMC3674207, DOI: 10.1016/j.neubiorev.2012.09.008.Peer-Reviewed Original Research
2011
Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment
Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment. Pharmacology & Therapeutics 2011, 132: 314-332. PMID: 21963369, PMCID: PMC3205262, DOI: 10.1016/j.pharmthera.2011.09.006.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTreatment-refractory OCDGlutamate-modulating agentsSmall clinical trialsNew treatment strategiesCompulsive disorderExcitatory neurotransmitter glutamatePathophysiology of OCDGlutamate abnormalitiesGlutamate dysregulationMonoaminergic neurotransmissionCurrent therapiesClinical trialsDopaminergic neurotransmissionTreatment strategiesCognitive-behavioral psychotherapyTherapeutic benefitAnimal modelsNeurotransmitter glutamateNeurochemical investigationsPathophysiologyNew therapeuticsDisordersRecent evidenceMedicationsThe Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis
Hannestad J, DellaGioia N, Bloch M. The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis. Neuropsychopharmacology 2011, 36: 2452-2459. PMID: 21796103, PMCID: PMC3194072, DOI: 10.1038/npp.2011.132.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsBiomarkersClinical Trials as TopicCytokinesDepressive Disorder, MajorHumansInflammation MediatorsTreatment OutcomeConceptsMajor depressive disorderInflammatory cytokinesSerum levelsAntidepressant treatmentInterleukin-6Depressive symptomsIL-1βCytokine levelsDepressive episodeDiagnosis of MDDTumor necrosis factor alphaPharmacological antidepressant treatmentAntidepressant medication treatmentClasses of antidepressantsStratified subgroup analysisIL-1 betaNecrosis factor alphaNormalization of levelsReuptake inhibitorsMedication treatmentPharmacological treatmentSubgroup analysisBrain dysfunctionDepressive disorderFactor alpha